{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:44:18Z","timestamp":1792143858009,"version":"4.4.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["21CA286210"],"award-info":[{"award-number":["21CA286210"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["OC230061"],"award-info":[{"award-number":["OC230061"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["P30CA118100"],"award-info":[{"award-number":["P30CA118100"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA265793"],"award-info":[{"award-number":["P50CA265793"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["CA210610"],"award-info":[{"award-number":["CA210610"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Therapeutic resistance remains a major challenge in advanced and recurrent endometrial cancer. Aberrant NOTCH signaling has been associated with aggressive tumor behavior and therapeutic resistance across multiple malignancies, yet its therapeutic significance in endometrial cancer remains incompletely defined. We investigated whether auranofin (AuR), a pleiotropic gold-containing compound that inhibits thioredoxin reductase and can disrupt RBPJ chromatin occupancy, alters platinum responsiveness in endometrial cancer models. Upper-quartile NOTCH3 copy number was associated with poorer overall survival in The Cancer Genome Atlas-Uterine Corpus Endometrial Carcinoma cohort, although this association was not retained with median-based stratification, continuous Cox proportional hazards modeling, or multivariable adjustment for clinicopathologic and molecular context. AuR treatment reduced RBPJ occupancy at canonical NOTCH target loci, including HES1 and HES4, across multiple endometrial cancer models, although this was not accompanied by significant changes in steady-state HES1 or HES4 transcript levels in AN3CA or ARK-1 cells. Stable NOTCH3 depletion produced context-dependent effects on AuR responsiveness and significantly enhanced cisplatin (CDDP) sensitivity in AN3CA cells. Pharmacologic AuR treatment similarly potentiated CDDP response in AN3CA cells and xenografts, resulting in reduced tumor burden and prolonged endpoint-free survival following combination treatment. In contrast, ARK-1 xenografts demonstrated limited additional benefit from combined AuR plus CDDP therapy despite detectable suppression of RBPJ occupancy. Together, these findings identify context-dependent NOTCH-associated therapeutic vulnerabilities in endometrial cancer and support further investigation of AuR-based platinum-sensitization strategies in biologically defined tumor contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>AuR disrupts RBPJ chromatin occupancy and enhances CDDP response in biologically distinct endometrial cancer contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0404","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:35:37Z","timestamp":1790706937000},"page":"2422-2433","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Auranofin Potentiates Cisplatin Response in the Setting of Context-Dependent NOTCH-Associated Signaling States in Endometrial Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7196-5710","authenticated-orcid":false,"given":"Robert J.","family":"Lake","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2063-5177","authenticated-orcid":false,"given":"Cynthia","family":"Tshibangu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9102-7439","authenticated-orcid":false,"given":"Niko J.","family":"Candia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-5663","authenticated-orcid":false,"given":"Quinn U.","family":"Abfalterer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"3Biomedical Sciences Graduate Program, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-4008","authenticated-orcid":false,"given":"Irina V.","family":"Lagutina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05fs6jp91","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico 4 Animal Models Shared Resource, Comprehensive Cancer Center, , Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0748-1272","authenticated-orcid":false,"given":"Christine","family":"Pauken","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-8990","authenticated-orcid":false,"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-9325","authenticated-orcid":false,"given":"Mara P.","family":"Steinkamp","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"5Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-4041","authenticated-orcid":false,"given":"Hua-Ying","family":"Fan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"publisher"}],"name":"University of New Mexico Comprehensive Cancer Center 1 Program in Cell and Molecular Oncology, , University of New Mexico Health Sciences Center, Albuquerque, New Mexico."},{"name":"2Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2026101604484331700_bib1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026101604484331700_bib2","article-title":"SEER cancer stat facts: uterine cancer (corpus Uteri)","author":"National Cancer Institute","year":"2025"},{"key":"2026101604484331700_bib3","volume-title":"Cancer facts & figures 2025","author":"American Cancer Society","year":"2025"},{"key":"2026101604484331700_bib4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/1078-0432.CCR-14-0809","article-title":"Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer","volume":"21","author":"Previs","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026101604484331700_bib5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41580-025-00835-2","article-title":"Modes of Notch signalling in development and disease","volume":"26","author":"Bray","year":"2025","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026101604484331700_bib6","doi-asserted-by":"publisher","first-page":"1542967","DOI":"10.3389\/fcell.2025.1542967","article-title":"Notch signaling in cancers: mechanism and potential therapy","volume":"13","author":"Chen","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2026101604484331700_bib7","doi-asserted-by":"publisher","first-page":"1277076","DOI":"10.3389\/fcell.2023.1277076","article-title":"Metastasis and cancer associated fibroblasts: taking it up a Notch","volume":"11","author":"Ghosh","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2026101604484331700_bib8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026101604484331700_bib9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","article-title":"Targeting the DLL\/Notch signaling pathway in cancer: challenges and advances in clinical development","volume":"22","author":"You","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026101604484331700_bib10","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.3390\/cancers13205106","article-title":"Targeting Notch to maximize chemotherapeutic benefits: rationale, advanced strategies, and future perspectives","volume":"13","author":"Zhdanovskaya","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026101604484331700_bib11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.34763\/jmotherandchild.20252901.d-24-00041","article-title":"Is there any difference in stem cell population between type I and type II endometrial cancer? A pilot study","volume":"29","author":"Muthuraman","year":"2025","journal-title":"J Mother Child"},{"key":"2026101604484331700_bib12","doi-asserted-by":"publisher","first-page":"694141","DOI":"10.3389\/fmolb.2021.694141","article-title":"The role of Notch3 signaling in cancer stemness and chemoresistance: molecular mechanisms and targeting strategies","volume":"8","author":"Xiu","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026101604484331700_bib13","doi-asserted-by":"publisher","first-page":"e0208221","DOI":"10.1371\/journal.pone.0208221","article-title":"Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer","volume":"13","author":"Polychronidou","year":"2018","journal-title":"PLoS One"},{"key":"2026101604484331700_bib14","doi-asserted-by":"publisher","first-page":"20778","DOI":"10.1073\/pnas.1019452108","article-title":"Notch1 regulates the expression of the multidrug resistance gene ABCC1\/MRP1 in cultured cancer cells","volume":"108","author":"Cho","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101604484331700_bib15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"2026101604484331700_bib16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ygyno.2017.09.025","article-title":"Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: an NRG Oncology\/Gynecologic Oncology Group study","volume":"147","author":"Devor","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2026101604484331700_bib17","doi-asserted-by":"publisher","first-page":"e1223","DOI":"10.1002\/ctm2.1223","article-title":"FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways","volume":"13","author":"Dixit","year":"2023","journal-title":"Clin Transl Med"},{"key":"2026101604484331700_bib18","doi-asserted-by":"publisher","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"key":"2026101604484331700_bib19","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101604484331700_bib20","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"2026101604484331700_bib21","doi-asserted-by":"publisher","first-page":"e52795","DOI":"10.1371\/journal.pone.0052795","article-title":"High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated","volume":"7","author":"Krakstad","year":"2012","journal-title":"PLoS One"},{"key":"2026101604484331700_bib22","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/0008-5472.CAN-13-2066","article-title":"Notch3 pathway alterations in ovarian cancer","volume":"74","author":"Hu","year":"2014","journal-title":"Cancer Res"},{"key":"2026101604484331700_bib23","doi-asserted-by":"publisher","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101604484331700_bib24","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1007\/s11033-023-08760-3","article-title":"High-grade serous ovarian carcinoma, the \u201cAchiles\u2019 hill\u201d for clinicians and molecular biologists: a molecular insight","volume":"50","author":"Bhattacharya","year":"2023","journal-title":"Mol Biol Rep"},{"key":"2026101604484331700_bib25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2353\/ajpath.2010.100316","article-title":"Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin","volume":"177","author":"Park","year":"2010","journal-title":"Am J Pathol"},{"key":"2026101604484331700_bib26","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/0008-5472.CAN-11-2181","article-title":"Defining NOTCH3 target genes in ovarian cancer","volume":"72","author":"Chen","year":"2012","journal-title":"Cancer Res"},{"key":"2026101604484331700_bib27","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1158\/0008-5472.CAN-05-3610","article-title":"Notch3 gene amplification in ovarian cancer","volume":"66","author":"Park","year":"2006","journal-title":"Cancer Res"},{"key":"2026101604484331700_bib28","doi-asserted-by":"publisher","first-page":"649205","DOI":"10.3389\/fcell.2021.649205","article-title":"Therapeutic targeting of Notch signaling: from cancer to inflammatory disorders","volume":"9","author":"Allen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026101604484331700_bib29","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1002\/onco.13627","article-title":"Gamma secretase inhibitors in cancer: a current perspective on clinical performance","volume":"26","author":"McCaw","year":"2021","journal-title":"Oncologist"},{"key":"2026101604484331700_bib30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/cells9061503","article-title":"Top Notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives","volume":"9","author":"Moore","year":"2020","journal-title":"Cells"},{"key":"2026101604484331700_bib31","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1073\/pnas.1922606117","article-title":"Pharmacological disruption of the Notch transcription factor complex","volume":"117","author":"Lehal","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101604484331700_bib32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/2767-9764.CRC-23-0333","article-title":"A phase I study of the pan-Notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors","volume":"3","author":"Hanna","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026101604484331700_bib33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/2472555220932552","article-title":"A novel flow cytometric assay to identify inhibitors of RBPJ-DNA interactions","volume":"25","author":"Lake","year":"2020","journal-title":"SLAS Discov"},{"key":"2026101604484331700_bib34","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1158\/2767-9764.CRC-25-0190","article-title":"Auranofin synergizes with cisplatin in reducing tumor burden of NOTCH-dependent ovarian cancer","volume":"5","author":"Lake","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026101604484331700_bib35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/antiox14101187","article-title":"The redox paradox: cancer\u2019s double-edged sword for malignancy and therapy","volume":"14","author":"Ranbhise","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"2026101604484331700_bib36","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1093\/nar\/gkz178","article-title":"HDAC1 negatively regulates selective mitotic chromatin binding of the Notch effector RBPJ in a KDM5A-dependent manner","volume":"47","author":"Dreval","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026101604484331700_bib37","doi-asserted-by":"publisher","first-page":"e1004284","DOI":"10.1371\/journal.pgen.1004284","article-title":"The sequence-specific transcription factor c-Jun targets Cockayne syndrome protein B to regulate transcription and chromatin structure","volume":"10","author":"Lake","year":"2014","journal-title":"PLoS Genet"},{"key":"2026101604484331700_bib38","doi-asserted-by":"publisher","first-page":"e1004204","DOI":"10.1371\/journal.pgen.1004204","article-title":"RBPJ, the major transcriptional effector of Notch signaling, remains associated with chromatin throughout mitosis, suggesting a role in mitotic bookmarking","volume":"10","author":"Lake","year":"2014","journal-title":"PLoS Genet"},{"key":"2026101604484331700_bib39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov Oncol"},{"key":"2026101604484331700_bib40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1128\/MCB.01408-13","article-title":"Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling","volume":"34","author":"Wakabayashi","year":"2014","journal-title":"Mol Cell Biol"},{"key":"2026101604484331700_bib41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.stem.2014.05.009","article-title":"Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling","volume":"15","author":"Paul","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2026101604484331700_bib42","doi-asserted-by":"publisher","first-page":"e3903","DOI":"10.1002\/cbf.3903","article-title":"Auranofin sensitizes breast cancer cells to paclitaxel mediated cell death via regulating FOXO3\/Nrf2\/Keap1 signaling pathway","volume":"42","author":"Deepika","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"2026101604484331700_bib43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.CAN-12-1733","article-title":"Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res"},{"key":"2026101604484331700_bib44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mc.22873","article-title":"Notch pathway inhibition using DAPT, a gamma-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma","volume":"58","author":"Dai","year":"2019","journal-title":"Mol Carcinog"},{"key":"2026101604484331700_bib45","doi-asserted-by":"publisher","first-page":"118532","DOI":"10.1016\/j.biopha.2025.118532","article-title":"Molecular impact of NOTCH signaling dysregulation on ovarian cancer progression, chemoresistance, and taxane response","volume":"191","author":"Koucka","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026101604484331700_bib46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/13543784.2021.1939305","article-title":"Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies","volume":"30","author":"Leung","year":"2021","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0404\/3834392\/crc-26-0404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2422\/3839651\/crc-26-0404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2422\/3839651\/crc-26-0404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:48:51Z","timestamp":1792140531000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2422\/789423\/Auranofin-Potentiates-Cisplatin-Response-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0404","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34572651","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572594","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572630","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572663","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572660","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572597","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572612","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572621","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572654","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572609","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572606","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34572618","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8778156","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}